NCT04754022.

Study name	TRICSIV: an international, multicentre, randomised controlled trial to assess transfusion thresholds in younger patients undergoing cardiac surgery
Methods	RCT (multicentre)
Participants	Adults (≥ 18 and ≤ 65 years of age) undergoing planned cardiac surgery Estimated enrolment: 1440
Interventions	Liberal group: transfusion at Hb < 9.5 g/dL threshold Restrictive group: transfusion at Hb < 7.5 g/dL threshold
Outcomes	Composite score of any 1 of the following events occurring 6 months after cardiac surgery: all‐cause mortality, myocardial infarction, new‐onset renal failure requiring dialysis, new focal neurological deficit (stroke)
Starting date	2021
Contact information	David Mazer; david.mazer@unityhealth.to Nadine Shehata; Mount Sinai Hospital, NY, USA
Notes	Trial registration (prospective): NCT04754022 Funding: not specified, but sponsor/collaborator is listed as Unity Health Toronto (Canada)